Skip to main content
Top
Published in: Virchows Archiv 3/2019

Open Access 01-03-2019 | Original Article

M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma

Authors: W. M. de Vries, I. H. Briaire-de Bruijn, P. P. G. van Benthem, A. G. L. van der Mey, P. C. W. Hogendoorn

Published in: Virchows Archiv | Issue 3/2019

Login to get access

Abstract

Macrophage colony stimulating factor and IL-34 are associated with clinical vestibular schwannoma progression. Investigating the biology behind vestibular schwannoma progression helps understanding tumor growth. Inflammation is important in the microenvironment of neoplasms. Macrophages are major players in the intratumoral infiltrate. These tumor-associated macrophages are known to stimulate angiogenesis and cell growth. M-CSF and IL-34 are cytokines that can regulate tumor-infiltrating macrophages. They are expressed by tumors and form potential targets for therapy. The goal of this study was to investigate these cytokines in vestibular schwannomas and to see if their expression is related to angiogenesis, macrophage numbers, cystic degeneration, and volumetric tumor progression. Immunohistochemical expression of M-CSF and IL-34 was analyzed in ten fast-growing vestibular schwannomas and in ten slow-growing vestibular schwannomas. Expression M-CSF and IL-34 were compared between fast- versus slow-growing and cystic versus non-cystic tumors. Data on macrophage numbers and microvessel density, known from earlier research, was also included. All tumors expressed M-CSF and its expression was higher in fast-growing tumors (p = 0.003) and in cystic tumors (p = 0.035). CD163 expression was higher in tumors with strong M-CSF expression (p = 0.003). All tumors expressed IL-34 as well, but no significant differences were found in relation to clinicopathological characteristics. This study demonstrated the expression of M-CSF and IL-34 in vestibular schwannomas. The results suggest that M-CSF is related to macrophage activity and tumor progression, making it a potential target for therapy. If a similar assumption can be made for IL-34 remains unclear.
Literature
1.
go back to reference Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: higher incidence than previously thought. OtolNeurotol 26(1):93–97 Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: higher incidence than previously thought. OtolNeurotol 26(1):93–97
2.
go back to reference Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72(5):791–800CrossRef Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72(5):791–800CrossRef
3.
go back to reference Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM (1994) Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3(6):885–891CrossRef Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM (1994) Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3(6):885–891CrossRef
4.
go back to reference Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515–521CrossRef Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515–521CrossRef
5.
go back to reference Stangerup SE, Caye-Thomasen P (2012) Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin N Am 45(2):257–268CrossRef Stangerup SE, Caye-Thomasen P (2012) Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin N Am 45(2):257–268CrossRef
6.
go back to reference Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P (2010) True incidence of vestibular schwannoma? Neurosurgery 67(5):1335–1340CrossRef Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P (2010) True incidence of vestibular schwannoma? Neurosurgery 67(5):1335–1340CrossRef
7.
go back to reference Howitz MF, Johansen C, Tos M, Charabi S, Olsen JH (2000) Incidence of vestibular schwannoma in Denmark, 1977-1995. Am J Otol 21(5):690–694PubMed Howitz MF, Johansen C, Tos M, Charabi S, Olsen JH (2000) Incidence of vestibular schwannoma in Denmark, 1977-1995. Am J Otol 21(5):690–694PubMed
8.
go back to reference Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12(1):14–18CrossRef Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12(1):14–18CrossRef
9.
go back to reference Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31(7):1135–1143CrossRef Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31(7):1135–1143CrossRef
10.
go back to reference Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di TE (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70(9):3483–3493CrossRef Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di TE (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70(9):3483–3493CrossRef
11.
go back to reference Paldor I, Chen AS, Kaye AH (2016) Growth rate of vestibular schwannoma. J Clin Neurosci 32:1–8CrossRef Paldor I, Chen AS, Kaye AH (2016) Growth rate of vestibular schwannoma. J Clin Neurosci 32:1–8CrossRef
12.
go back to reference de Vries M, Briaire-de BI, Malessy MJ, de Bruine SF, van der Mey AG, Hogendoorn PC (2013) Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 34(2):347–352CrossRef de Vries M, Briaire-de BI, Malessy MJ, de Bruine SF, van der Mey AG, Hogendoorn PC (2013) Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 34(2):347–352CrossRef
13.
go back to reference de Vries M, Hogendoorn PC, Briaire-de BI, Malessy MJ, van der Mey AG (2012) Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch 460(6):629–636CrossRef de Vries M, Hogendoorn PC, Briaire-de BI, Malessy MJ, van der Mey AG (2012) Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch 460(6):629–636CrossRef
14.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444CrossRef Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444CrossRef
15.
go back to reference Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065–1073CrossRef Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065–1073CrossRef
16.
go back to reference Allen M, Louise JJ (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223(2):162–176CrossRef Allen M, Louise JJ (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223(2):162–176CrossRef
17.
go back to reference Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416CrossRef Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416CrossRef
18.
go back to reference Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA (2016) Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta 1865(1):23–34PubMed Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA (2016) Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta 1865(1):23–34PubMed
19.
go back to reference Svensson J, Jenmalm MC, Matussek A, Geffers R, Berg G, Ernerudh J (2011) Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol 187(7):3671–3682CrossRef Svensson J, Jenmalm MC, Matussek A, Geffers R, Berg G, Ernerudh J (2011) Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol 187(7):3671–3682CrossRef
20.
go back to reference Ding J, Guo C, Hu P, Chen J, Liu Q, Wu X, Cao Y, Wu J (2016) CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol 49(5):2064–2074CrossRef Ding J, Guo C, Hu P, Chen J, Liu Q, Wu X, Cao Y, Wu J (2016) CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol 49(5):2064–2074CrossRef
21.
go back to reference Yang L, Wu Q, Xu L, Zhang W, Zhu Y, Liu H, Xu J, Gu J (2015) Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer 15:67CrossRef Yang L, Wu Q, Xu L, Zhang W, Zhu Y, Liu H, Xu J, Gu J (2015) Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer 15:67CrossRef
22.
go back to reference Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59(5):300–305CrossRef Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59(5):300–305CrossRef
23.
go back to reference Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science (New York, NY) 320(5877):807–811CrossRef Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science (New York, NY) 320(5877):807–811CrossRef
24.
go back to reference Nakamichi Y, Udagawa N, Takahashi N (2013) IL-34 and CSF-1: similarities and differences. J Bone Miner Metab 31(5):486–495CrossRef Nakamichi Y, Udagawa N, Takahashi N (2013) IL-34 and CSF-1: similarities and differences. J Bone Miner Metab 31(5):486–495CrossRef
25.
go back to reference Segaliny AI, Brion R, Brulin B, Maillasson M, Charrier C, Teletchea S, Heymann D (2015) IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. Cytokine 76(2):170–181CrossRef Segaliny AI, Brion R, Brulin B, Maillasson M, Charrier C, Teletchea S, Heymann D (2015) IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. Cytokine 76(2):170–181CrossRef
26.
go back to reference Segaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D (2015) Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer 137(1):73–85CrossRef Segaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D (2015) Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer 137(1):73–85CrossRef
27.
go back to reference Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI (2016) Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res 76(20):6030–6042CrossRef Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI (2016) Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res 76(20):6030–6042CrossRef
28.
go back to reference Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovee JV, Hogendoorn PC, Danen EH (2015) Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 236(3):348–359CrossRef Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovee JV, Hogendoorn PC, Danen EH (2015) Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 236(3):348–359CrossRef
29.
go back to reference Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173–177CrossRef Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173–177CrossRef
30.
go back to reference Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5(1):53CrossRef Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5(1):53CrossRef
31.
go back to reference Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG (2017) Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol Res 5(7):535–546CrossRef Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG (2017) Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol Res 5(7):535–546CrossRef
32.
go back to reference Zhou RP, Wu XS, Xie YY, Dai BB, Hu W, Ge JF, Chen FH (2016) Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology 149(4):362–373CrossRef Zhou RP, Wu XS, Xie YY, Dai BB, Hu W, Ge JF, Chen FH (2016) Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology 149(4):362–373CrossRef
Metadata
Title
M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma
Authors
W. M. de Vries
I. H. Briaire-de Bruijn
P. P. G. van Benthem
A. G. L. van der Mey
P. C. W. Hogendoorn
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 3/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-018-2503-1

Other articles of this Issue 3/2019

Virchows Archiv 3/2019 Go to the issue